Clinical trials: Stage IV Breast Cancer AJCC V7
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones
This phase II trial studies how well radium-223 dichloride and paclitaxel work in treating patients with advanced breast cancer that has spread to the bones.
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone
- Trial name
- NCT04090398
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 30 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Ovarian Cancer
Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00019916
- Testing
- aldesleukin, p53 peptide vaccine, in vitro-treated peripheral blood stem cell transplantation
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Advanced Breast Cancer
Phase II Dasatinib Study in Advanced Breast Cancer
The purpose of this study is to find out if dasatinib will safely reduce the size or spread of your tumor.
- Trial name
- NCT00546104
- Testing
- Dasatinib
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Duke University
Cancer
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003867
- Testing
- capecitabine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Breast Cancer
S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using goserelin and anastrozole may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00217659
- Testing
- anastrozole, goserelin acetate
- Where
- 57 sites in United States
- Sponsor
- SWOG Cancer Research Network
Stage IV Breast Cancer
Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients
The purpose of this study is to compare the effect of primary resection combined with systemic therapy and pure systemic therapy on the overall survival of patients with stage Ⅳ breast cancer.
- Trial name
- NCT04199520
- Testing
- surgery combined with systemic therapy, systemic therapy
- Where
- China
- Sponsor
- Henan Cancer Hospital
Breast Cancer
Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Aldesleukin may stimulate the white blood cells to kill breast cancer cells.
- Trial name
- NCT00784524
- Testing
- allogeneic large multivalent immunogen breast cancer vaccine, aldesleukin
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Breast Cancer
Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating women with metastatic breast…
- Trial name
- NCT00003540
- Testing
- gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have metastatic or…
- Trial name
- NCT00004182
- Testing
- irinotecan hydrochloride
- Where
- 2 sites in United States
- Sponsor
- Northwestern University
Advanced Breast Carcinoma, Advanced Colon Carcinoma
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have…
- Conditions
- Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma
- Trial name
- NCT04704661
- Testing
- Biopsy Procedure, Biospecimen Collection, Ceralasertib
- Where
- 23 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Lung Cancer
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
RATIONALE: Vaccines may make the body build an immune response to tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood.
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00005023
- Testing
- HER-2/neu peptide vaccine, sargramostim
- Where
- United States
- Sponsor
- University of Washington
Recurrent Breast Cancer, Stage IA Breast Cancer
Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery
This clinical trial studies azacitidine in treating patients with triple negative stage I-IV invasive breast cancer that can be removed by surgery.
- Conditions
- Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT01292083
- Testing
- azacitidine, laboratory biomarker analysis, immunohistochemistry staining method
- Sponsor
- University of Southern California
Cardiotoxicity, HER2/Neu Positive
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment.
- Conditions
- Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma
- Trial name
- NCT03418961
- Testing
- Carvedilol, Laboratory Biomarker Analysis, Patient Observation
- Where
- 590 sites in United States, Puerto Rico and 2 more
- Volunteers
- 491 people
- Sponsor
- SWOG Cancer Research Network
Ovarian Epithelial Cancer Stage III, Stage IV Ovarian Cancer
Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients
The purpose of this study is to determine the effectiveness, safety, tolerability and best dose of Lapatinib (GW572016) in combination with carboplatin and paclitaxel.
- Conditions
- Ovarian Epithelial Cancer Stage III, Stage IV Ovarian Cancer, Stage IV Breast Cancer
- Trial name
- NCT00316407
- Testing
- lapatinib (GW572016), Carboplatin, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Swedish Medical Center
Breast Cancer, Metastatic Cancer
Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help doctors find CNS metastases and plan treatment.
- Trial name
- NCT00398437
- Testing
- trastuzumab, chemotherapy, magnetic resonance imaging
- Where
- 3 sites in Belgium
- Volunteers
- 96 people
- Sponsor
- Jules Bordet Institute
Breast Cancer
Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some patients may develop a resistance to chemotherapy drugs.
- Trial name
- NCT00003253
- Testing
- paclitaxel, antitumor drug screening assay
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Oncotech
Breast Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00662129
- Testing
- bevacizumab, gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- 92 sites in United States
- Volunteers
- 50 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003927
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00622466
- Testing
- paclitaxel, sorafenib tosylate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer
Improving Communication With Patients With Breast Cancer
RATIONALE: An education program based on patients' health communication needs may improve patients' overall healthcare experience and sense of control.
- Trial name
- NCT00276822
- Testing
- communication intervention
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University